share_log

Canaccord Genuity Initiates Coverage On KemPharm With Buy Rating, Announces Price Target of $20

Canaccord Genuity Initiates Coverage On KemPharm With Buy Rating, Announces Price Target of $20

Canaccord Genuity以买入评级启动对KempHarm的报道,宣布目标股价为20美元
Benzinga Real-time News ·  2022/09/15 06:41

Canaccord Genuity analyst Sumant Kulkarni initiates coverage on KemPharm (NASDAQ:KMPH) with a Buy rating and announces Price Target of $20.

Canaccord Genuity分析师苏曼特·库尔卡尼以买入评级开始对KempHarm(纳斯达克股票代码:KMPH)进行报道,并宣布目标股价为20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发